middl
east
respiratori
syndrom
coronaviru
emerg
viru
caus
sever
pneumonia
ill
exhibit
high
mortal
first
known
human
case
occur
jordan
caus
viru
detect
identifi
later
year
saudi
sinc
case
report
countri
across
envelop
viru
carri
genom
posit
sens
viru
consid
primarili
zoonot
viru
belong
lineag
c
betacoronaviru
thu
close
relat
bat
coronavirus
sever
studi
shown
bat
camel
like
anim
reservoir
accumul
evid
point
viru
transmiss
dromedari
camel
case
mani
viral
diseas
effect
therapi
mer
lack
support
care
avail
treatment
option
attempt
develop
effect
vaccin
infect
led
promis
result
still
earli
high
morbid
mortal
rate
well
potenti
caus
epidem
highlight
need
novel
drug
discoveri
develop
effect
safe
therapeut
sever
effort
undertaken
identifi
select
potent
small
molecul
promis
compound
identifi
via
screen
drug
small
molecul
use
system
vitro
target
homolog
identifi
sever
acut
respiratori
syndrom
coronaviru
investig
review
hilgenfeld
among
main
proteinas
also
known
proteas
consid
import
potenti
target
due
essenti
role
viral
life
coronaviru
genom
encod
replicas
polyprotein
process
yield
intermedi
matur
nonstructur
protein
respons
mani
aspect
viru
enzym
start
attract
interest
target
drug
develop
howev
data
enzym
inhibit
scarc
comprehens
explor
drug
target
mani
potent
enzym
inhibitor
elabor
silico
model
obtain
use
inhibitor
prove
fruitless
identif
inhibitor
model
studi
conduct
group
data
publish
interestingli
enzym
differ
cov
strain
known
share
signific
sequenc
structur
homolog
provid
strong
structur
basi
design
sequenc
align
studi
show
activ
site
residu
particip
inhibitor
bind
conserv
sequenc
figur
therefor
bat
investig
surrog
model
novel
peptidomimet
inhibitor
identifi
use
enzym
studi
use
set
peptidomimet
inhibitor
report
st
john
et
conduct
extens
comput
model
studi
model
effort
aim
establish
pharmacophor
model
use
search
queri
virtual
screen
potenti
inhibitor
method
use
develop
previous
group
pharmacophor
compar
intermolecular
contact
analysi
dbcica
pharmacophor
model
approach
use
success
identifi
potent
inhibitor
sever
drug
identifi
hit
test
vitro
inhibitori
activ
enzym
structur
biolog
data
previous
identifi
inhibitor
report
st
john
et
tabl
use
model
bioactiv
inhibitor
express
concentr
test
compound
inhibit
activ
case
unavail
valu
ie
tabl
correspond
estim
extrapol
base
report
inhibitori
percentag
assum
linear
relationship
logarithm
measur
valu
use
pharmacophor
model
correl
bioactiv
data
linearli
free
energi
chang
chiral
center
unknown
configur
mark
unknown
invers
chiral
center
sampl
conform
gener
compound
use
explor
pharmacophor
space
seri
establish
model
step
describ
model
workflow
detail
section
select
optim
pharmacophor
conduct
find
optim
combin
pharmacophor
model
capabl
explain
bioactiv
variat
across
whole
set
collect
train
compound
tabl
qsar
model
done
use
genet
function
algorithm
gfa
gener
combin
descriptor
physicochem
pharmacophor
section
subsequ
multipl
linear
regress
mlr
analys
use
assess
qualiti
select
descriptor
combin
ie
explain
bioactiv
variat
within
collect
inhibitor
qsar
model
perform
use
train
set
compound
total
set
inhibitor
valid
use
r
r
loo
predict
r
r
press
randomli
select
test
set
inhibitor
describ
section
test
set
select
rank
total
inhibitor
accord
valu
everi
fifth
compound
select
test
set
start
end
dock
studi
perform
use
subset
compound
peptidomimet
inhibitor
known
absolut
stereochemistri
tabl
coordin
retriev
protein
data
bank
pdb
code
protein
structur
modifi
ad
hydrogen
atom
charg
protein
atom
use
discoveri
studio
version
accelri
inc
san
diego
use
subsequ
dock
experi
without
energi
minim
dock
conduct
use
libdock
dock
algorithm
dock
ligand
remov
hydrogen
atom
activ
site
guid
bind
cdocker
simul
annealingmolecular
dynam
method
implement
simul
anneal
search
stabl
dock
ligand
dock
engin
consid
flexibl
ligand
treat
receptor
rigid
detail
dock
engin
correspond
dock
set
describ
section
dock
conformerspos
score
use
score
function
jain
pmf
section
cycl
use
engin
repeat
cover
possibl
dock
combin
result
presenc
absenc
crystallograph
explicit
water
molecul
within
bind
site
take
account
score
function
turn
highest
score
dock
conformerpos
inhibitor
chosen
use
subsequ
compar
intermolecular
contact
analysi
dbcica
step
result
dockingscor
combin
compound
score
correspond
score
function
dock
score
cycl
repeat
time
cover
combin
dock
condit
ie
presenc
absenc
explicit
water
molecul
result
dockingscor
set
use
dbcica
model
describ
section
describ
detail
dbcica
model
success
dbcica
model
use
guid
manual
build
pharmacophor
section
optim
pharmacophor
structur
ligand
base
valid
use
receiv
oper
characterist
roc
curv
analysi
assess
abil
model
correctli
classifi
group
compound
activ
inact
section
matthew
correl
coeffici
mcc
also
undertaken
addit
addit
exclus
sphere
ad
use
modul
discoveri
studio
improv
roc
properti
pharmacophor
section
select
pharmacophor
use
search
queri
screen
nation
cancer
institut
nci
new
inhibitor
hit
captur
pharmacophor
filter
lipinski
criteria
ensur
good
pharmacokinet
smile
arbitrari
target
specif
smart
filter
section
remov
reactiv
ligand
ie
alkyl
halid
michael
acceptor
remain
hit
fit
correspond
individu
pharmacophor
fit
valu
substitut
qsar
model
predict
hit
bioactiv
hit
select
vitro
test
use
vote
system
minim
influenc
predict
hit
priorit
system
hit
fit
valu
hit
overal
qsar
predict
cast
vote
one
valu
within
top
captur
hit
otherwis
vote
zero
similarli
hit
captur
success
pharmacophor
pool
togeth
filter
accord
lipinski
smart
hit
dock
bind
pocket
use
dockingscor
condit
success
dbcica
model
result
dock
pose
analyz
critic
contact
accord
success
dbcica
model
sum
critic
contact
hit
compound
use
predict
correspond
valu
hit
select
vitro
test
use
similar
vote
system
describ
dock
solut
cast
vote
one
predict
valu
within
top
captur
hit
otherwis
cast
vote
zero
express
escherichia
coli
cell
presenc
carbenicillin
describ
cell
harvest
centrifug
minut
pellet
store
use
purif
perform
use
consecut
step
chromatographi
deae
chromatographi
mono
chromatographi
chromatographi
describ
produc
purifi
use
modifi
protocol
agnihothram
et
final
protein
yield
calcul
base
measur
total
activ
unit
productmin
specif
activ
unitsmg
milligram
protein
obtain
biorad
protein
assay
chromatograph
step
inhibit
assay
conduct
describ
acquir
hit
screen
inhibit
mer
concentr
duplic
assay
contain
follow
assay
buffer
hepe
mgml
bsa
dtt
compound
potent
compound
train
set
tabl
st
john
et
al
tabl
use
posit
control
assay
conduct
costar
eiaria
half
area
flat
bottom
black
polystyren
plate
corn
new
york
total
inhibitor
stock
dimethyl
sulfoxid
dmso
ad
enzym
assay
buffer
mixtur
incub
minut
reaction
initi
addit
substrat
custom
synthes
reson
energi
transfer
substrat
peptid
follow
sequenc
hilytefluor
produc
final
concentr
substrat
fluoresc
intens
reaction
measur
time
rel
fluoresc
unit
rfut
period
minut
use
excit
wavelength
nm
bandwidth
nm
monitor
emiss
nm
bandwidth
nm
use
biotek
synergi
multimod
micropl
reader
inhibit
hit
compound
monitor
follow
chang
rfu
time
use
initi
slope
progress
curv
determin
initi
rate
vi
percent
inhibit
enzym
determin
use
follow
equat
valu
determin
ambient
temperatur
assay
perform
triplic
follow
buffer
hepe
mgml
bsa
dtt
kinet
assay
conduct
costar
eiaria
half
area
flat
bottom
black
polystyren
plate
corn
ny
inhibitor
test
concentr
rang
total
inhibitor
stock
dmso
ad
enzym
assay
buffer
mixtur
incub
minut
reaction
initi
addit
substrat
produc
final
concentr
substrat
fluoresc
intens
reaction
measur
time
rfut
period
minut
use
excit
wavelength
nm
bandwidth
nm
monitor
emiss
nm
bandwidth
nm
use
biotek
synergi
multimod
micropl
reader
percent
inhibit
enzym
plot
function
inhibitor
concentr
sigmaplot
enzym
kinet
wizard
use
fit
triplic
percent
inhibit
data
associ
standard
error
nonlinear
type
regress
model
determin
enzym
use
follow
equat
inhibit
imax
percent
maximum
inhibit
error
valu
determin
error
fit
paramet
control
perform
enzym
substrat
waswer
omit
fluoresc
attenu
control
carri
ad
inhibitor
cleav
substrat
reaction
mixtur
ident
use
inhibit
assay
pharmacophor
space
inhibitor
extens
explor
hypogen
automat
run
perform
care
select
train
subset
compris
compound
section
tabl
train
compound
subset
select
way
ensur
set
repres
common
bind
mode
guarante
bioactiv
differ
among
member
attribut
presenc
absenc
pharmacophor
featur
appli
strategi
allow
effect
explor
pharmacophor
space
inhibitor
help
identifi
pharmacophor
hypothes
repres
possibl
bind
mode
assum
run
result
success
pharmacophor
model
cluster
use
hierarch
averag
linkag
method
avail
catalyst
best
repres
model
use
subsequ
qsar
model
section
fit
valu
obtain
map
repres
pharmacophor
inhibitor
enrol
togeth
select
descriptor
independ
variabl
qsar
analysi
genet
function
algorithm
combin
mlr
analys
use
select
differ
combin
pharmacophor
molecular
descriptor
capabl
explain
bioactiv
variat
among
collect
inhibitor
howev
attempt
achiev
statist
success
qsar
model
fail
prompt
use
ligand
effici
le
heavi
atom
count
altern
respons
variabl
instead
best
qsar
model
summar
equat
figur
b
show
correspond
scatter
plot
experiment
versu
estim
bioactiv
train
test
inhibitor
n
number
train
compound
use
gener
equat
f
fisher
statist
r
loo
correl
coeffici
r
press
predict
r
determin
randomli
select
test
compound
aromaticbond
number
aromat
bond
molecul
dipol
dipolex
dipoley
dipol
moment
descriptor
indic
strength
orient
behavior
molecul
electrostat
field
lumo
energi
lowest
unoccupi
molecular
hypo
hypo
hypo
repres
fit
valu
train
compound
correspond
pharmacophor
see
tabl
figur
show
pharmacophor
fit
potent
train
compound
appear
aromaticbond
descriptor
combin
posit
slope
qsar
equat
indic
inhibitori
activ
directli
proport
number
aromat
ring
inhibitor
structur
expect
bind
pocket
rich
aromat
amino
acid
appar
ligand
aromat
ring
stack
aromat
residu
bind
pocket
like
lead
high
bind
affin
howev
emerg
sever
dipol
moment
descriptor
dipol
dipolex
dipoley
combin
posit
neg
regress
coeffici
equat
suggest
obscur
role
ligand
dipol
moment
bind
within
pocket
emerg
lumo
equat
combin
neg
slope
suggest
affin
favor
electrophil
ligand
perhap
due
certain
aromat
center
bind
pocket
eg
aromat
ring
emerg
hypo
hypo
equat
suggest
possibl
multipl
complementari
bind
mode
exhibit
ligand
within
bind
pocket
receiv
oper
characterist
analysi
pharmacophor
show
hypo
hypo
significantli
superior
hypo
tabl
furthermor
mcc
pharmacophor
reflect
weak
classif
abil
hypo
tabl
poor
classif
power
hypo
prompt
us
exclud
subsequ
model
effort
howev
hypo
hypo
figur
b
pharmacophor
featur
common
hydrophob
hbic
ring
aromat
ringarom
hydrogen
bond
acceptor
hba
featur
close
resembl
pharmacophor
combin
equival
contribut
bioactiv
indic
slope
qsar
equat
suggest
might
repres
common
bind
mode
assum
ligand
within
bind
pocket
therefor
pharmacophor
merg
singl
bind
model
hypo
figur
interestingli
hypo
show
notic
improv
distinguish
activ
decoy
indic
roc
analysi
mcc
valu
tabl
merg
pharmacophor
share
common
featur
report
improv
perform
pharmacophor
captur
activ
addit
hypo
modifi
ad
exclus
sphere
section
tabl
enhanc
roc
profil
tabl
exclus
volum
resembl
inaccess
region
within
bind
site
figur
show
steric
refin
version
hypo
complement
eight
exclus
volum
moreov
hypo
map
potent
ligand
way
close
resembl
interact
observ
structur
compound
figur
close
proxim
ligand
thiophenoyl
moieti
sulfid
figur
suggest
presenc
mutual
hydrophob
interact
correl
map
ring
hbic
featur
hypo
figur
similarli
map
carbonyl
thiophenoyl
moieti
hba
featur
hypo
figur
agre
hydrogen
bond
interact
connect
carbonyl
thiol
figur
likewis
hydrogen
bond
interact
connect
amid
nh
ligand
peptid
carbonyl
via
bridg
water
molecul
agre
map
nh
hydrogen
bond
donor
hbd
featur
hypo
figur
map
ligand
benzotriazol
ring
ringarom
featur
hypo
figur
correl
stack
ring
system
peptid
amid
connect
bind
pocket
figur
final
hydrogen
bond
interact
anchor
ligand
tertiari
amid
carbonyl
peptid
nh
correspond
fit
carbonyl
hba
featur
hypo
figur
find
show
hypo
repres
valid
bind
mode
exhibit
ligand
within
bind
pocket
interact
highlight
pharmacophor
featur
within
model
like
critic
affin
pharmacophor
model
obtain
use
dbcica
approach
subset
inhibitor
tabl
dock
bind
pocket
use
section
conformerspos
base
score
function
align
togeth
construct
correspond
dbcica
model
genet
algorithm
use
search
best
combin
intermolecular
contact
capabl
explain
bioactiv
variat
across
train
compound
tabl
show
contact
distanc
threshold
number
posit
neg
contact
statist
criteria
best
dbcica
model
tabl
show
critic
bind
site
contact
atom
propos
optim
dbcica
model
dbcica
model
exhibit
excel
statist
criteria
anticip
act
good
templat
build
correspond
pharmacophor
model
tabl
figur
show
dbcica
model
tabl
convert
correspond
pharmacophor
model
hypo
exampl
emerg
signific
posit
contact
atom
figur
combin
consensu
among
potent
dock
ligand
posit
hydrophob
alkyl
cycloalkyl
aromat
ring
nearbi
within
figur
prompt
us
place
hbic
featur
onto
ligand
group
figur
like
hydrophob
fragment
ligand
interact
side
chain
similarli
emerg
amid
nh
signific
posit
contact
combin
agreement
among
dock
potent
train
compound
place
central
benzen
ring
near
contact
suggest
place
hbic
featur
onto
benzen
ligand
fragment
clearli
ring
involv
hydrophob
interact
nearbi
thiol
instead
nearest
aromat
amino
acid
residu
away
explain
decis
place
hbic
featur
onto
region
ligand
ie
rather
ringarom
featur
likewis
appear
posit
contact
point
combin
agreement
among
potent
hit
posit
benzotriazol
close
suggest
place
hydrophob
aromat
hbicarom
featur
onto
benzotriazol
moieti
figur
reason
ad
hbicarom
featur
onto
ring
instead
vector
ringarom
featur
benzotriazol
although
dock
near
imidazol
exhibit
typic
align
residu
contrast
appear
posit
contact
combin
consensu
among
dock
potent
inhibitor
project
thiophen
ring
close
nearbi
imidazol
suggest
mutual
interact
involv
ligand
thiophen
imidazol
observ
support
place
ringarom
featur
onto
thiophen
ring
emerg
posit
contact
amid
nh
agreement
dock
compound
place
central
amid
oxygen
close
nh
indic
presenc
hydrogen
bond
interact
suggest
place
hba
featur
onto
ligand
amid
carbonyl
group
figur
interact
like
involv
hydrogen
bond
peptid
amid
nh
final
contact
point
neg
correl
bioactiv
assum
repres
area
steric
clash
bound
ligand
therefor
contact
use
defin
exclus
volum
within
vicin
bind
pocket
shown
figur
strategi
use
translat
optim
dbcica
model
tabl
correspond
pharmacophor
model
figur
x
z
coordin
result
pharmacophor
shown
tabl
subsequ
valid
use
roc
analysi
tabl
illustr
excel
classif
power
pharmacophor
distinguish
activ
decoy
matthew
correl
coeffici
valu
indic
dbcica
model
superior
classif
abil
pharmacophor
steric
refin
merg
pharmacophor
hypo
pharmacophor
hypo
hypo
use
search
queri
screen
nci
virtual
databas
small
molecul
inhibitor
captur
hit
filter
lipinski
smart
filter
section
hit
fit
compon
pharmacophor
ie
hypo
hypo
hypo
fit
valu
substitut
equat
predict
bioactiv
top
compound
hit
priorit
use
vote
system
describ
section
avail
nci
open
chemic
repositori
acquir
vitro
test
hand
filter
hit
dock
protein
use
dock
condit
success
dbcica
model
tabl
predict
correspond
inhibitori
valu
section
hit
rank
priorit
use
vote
system
describ
section
top
compound
acquir
vitro
test
thu
total
compound
nci
open
chemic
repositori
acquir
test
total
nci
figur
deriv
hit
dbcica
deriv
hit
compound
acquir
screen
vitro
determin
inhibitori
activ
hit
concentr
enzym
assay
use
studi
care
design
avoid
mislead
fals
posit
prevent
wast
promiscu
compound
ad
albumin
dtt
reaction
mixtur
tabl
show
inhibit
hit
captur
dbcica
deriv
pharmacophor
respect
singl
compound
nci
code
test
hit
captur
pharmacophor
show
inhibitori
activ
howev
compound
molecular
fragment
known
caus
pan
assay
interfer
therefor
consid
hit
character
three
compound
hit
nci
code
tabl
show
unexpectedli
high
neg
valu
activ
tabl
sever
control
perform
either
substrat
enzym
omit
assay
data
shown
none
hit
show
evid
fluoresc
interfer
might
possibl
compound
act
activ
enzym
howev
evid
still
need
support
hypothesi
previous
observ
design
revers
peptidomimet
inhibitor
act
activ
low
compound
concentr
result
induc
therefor
hit
discuss
current
public
singl
compound
nci
code
dbcica
deriv
hit
show
inhibitori
activ
tabl
figur
activ
compar
posit
control
enzym
compound
figur
howev
compound
fail
show
signific
inhibitori
activ
puriti
confirm
use
nuclear
magnet
reson
mass
spectroscopi
figur
anoth
compound
found
exhibit
bit
lower
activ
enzym
inhibit
puriti
confirm
use
nuclear
magnet
reson
mass
spectroscopi
figur
compound
nci
code
share
common
phenylsulfonamid
fragment
amen
chemic
modif
compound
captur
hypo
hypo
pharmacophor
tabl
figur
show
hit
map
dbcica
pharmacophor
model
control
conduct
describ
rule
fluoresc
interfer
none
hit
show
signific
flouresc
assay
buffer
enzym
substrat
presenc
enzym
substrat
presenc
substrat
enzym
data
shown
howev
concentr
show
approxim
attenu
cleav
substrat
fluoresc
data
shown
show
moder
appar
valu
respect
figur
shape
activ
curv
compound
linear
inhibit
fluoresc
maximum
inhibit
indic
influenc
inner
filter
effect
figur
inner
filter
effect
one
major
challeng
usual
encount
enzym
low
hit
rate
observ
studi
justifi
limit
avail
mani
hit
nci
open
chemic
repositori
henc
limit
number
test
hit
hit
also
limit
avail
publish
potent
inhibitor
use
train
set
model
enzym
inhibit
obvious
predict
abil
comput
model
much
depend
compound
use
model
train
compound
use
current
studi
compound
exhibit
valu
effect
start
train
set
promin
model
model
henc
explain
poor
qualiti
model
indic
low
mcc
valu
clearli
qualiti
train
set
pivot
factor
determin
predict
valid
obtain
pharmacophor
also
worth
note
activ
design
nonpeptidomimet
small
molecul
inhibitor
proteas
often
challeng
uniqu
chemistri
cleavag
transit
state
proteas
cleav
substrat
induc
fit
recent
special
attent
paid
bat
coronavirus
two
deadli
emerg
coronavirus
caus
unexpect
human
diseas
outbreak
suggest
origin
bat
consid
threat
global
public
health
transmiss
far
limit
seriou
concern
pandem
potenti
rais
therefor
urgent
need
develop
effect
safe
treatment
studi
explor
pharmacophor
space
recent
identifi
peptidomem
independ
approach
pharmacophor
model
pharmacophor
construct
approach
success
result
identif
novel
potent
inhibitor
wide
varieti
target
pharmacophor
model
method
pharmacophor
deriv
extens
explor
space
care
select
variabl
small
subset
inhibitor
pharmacophor
allow
compet
within
context
classic
qsar
use
gfa
mlr
identifi
combin
result
finest
estim
bioactiv
dbcica
model
hand
pharmacophor
construct
method
reli
accur
select
success
dockingscor
condit
combin
success
criterion
abil
dock
run
align
potent
ligand
way
would
allow
form
contact
unattain
ligand
dbcica
consid
qsar
correl
ligand
affin
contact
certain
bind
site
spot
use
gfa
mlr
success
dbcica
model
translat
bind
model
pharmacophor
use
silico
screen
tool
virtual
databas
appli
robust
comput
method
model
inhibitor
tool
identifi
inhibitor
model
assist
identif
hit
compound
moder
appar
activ
identifi
inhibitor
share
novel
nonpeptidomimet
scaffold
amen
medicin
chemistri
optim
effort
despit
fair
inhibitori
activ
scaffold
repres
potenti
start
point
discoveri
novel
antivir
sever
success
exampl
histori
drug
discoveri
start
hit
show
enzym
inhibit
exampl
millimolar
inhibitor
start
point
develop
zanamivir
first
influenza
neuraminidas
inhibitor
introduc
importantli
establish
pharmacophor
model
aid
tool
advanc
understand
small
molecul
recognit
coronaviru
enzym
pharmacophor
obtain
model
inhibitor
reveal
structur
featur
need
potent
enzym
inhibitor
design
dbcica
model
model
highlight
potenti
region
pocket
could
target
use
small
nonpeptidomimet
molecul
knowledg
valuabl
success
develop
inhibitor
drug
public
base
work
support
award
us
civilian
research
develop
foundat
crdf
global
nation
scienc
foundat
cooper
agreement
task
order
opinion
find
conclus
recommend
express
materi
author
necessarili
reflect
view
crdf
global
